Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), 4D Molecular Therapeutics (FDMT) and Sanofi (OtherSNYNF)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Structure Therapeutics, Inc. Sponsored ADR (GPCR – Research Report), 4D Molecular Therapeutics (FDMT – Research Report) and Sanofi (SNYNF – Research Report).

Structure Therapeutics, Inc. Sponsored ADR (GPCR)

In a report issued on May 10, Evan Seigerman from BMO Capital initiated coverage with a Buy rating on Structure Therapeutics, Inc. Sponsored ADR and a price target of $83.00. The company’s shares closed last Friday at $35.82.

According to TipRanks.com, Seigerman is a 3-star analyst with an average return of 3.4% and a 44.5% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, AbCellera Biologics, and Morphic Holding.

Currently, the analyst consensus on Structure Therapeutics, Inc. Sponsored ADR is a Strong Buy with an average price target of $83.00, implying a 124.8% upside from current levels. In a report issued on May 10, Piper Sandler also maintained a Buy rating on the stock with a $93.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

4D Molecular Therapeutics (FDMT)

BMO Capital analyst Kostas Biliouris maintained a Buy rating on 4D Molecular Therapeutics yesterday and set a price target of $63.00. The company’s shares closed last Friday at $25.70.

According to TipRanks.com, Biliouris has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -5.6% and a 28.4% success rate. Biliouris covers the Healthcare sector, focusing on stocks such as Centessa Pharmaceuticals, BioMarin Pharmaceutical, and Crispr Therapeutics AG.

4D Molecular Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $46.00, which is an 82.6% upside from current levels. In a report issued on May 9, RBC Capital also maintained a Buy rating on the stock with a $40.00 price target.

Sanofi (SNYNF)

In a report released today, Emmanuel Papadakis from Deutsche Numis maintained a Sell rating on Sanofi, with a price target of EUR80.00. The company’s shares closed last Friday at $102.52.

According to TipRanks.com, Papadakis is a 4-star analyst with an average return of 6.4% and a 58.8% success rate. Papadakis covers the Healthcare sector, focusing on stocks such as Roche Holding AG, BioNTech SE, and Moderna.

Sanofi has an analyst consensus of Moderate Buy, with a price target consensus of $113.43.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on GPCR:

• Structure Therapeutics initiated with an Overweight at Cantor Fitzgerald